Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer. (Q54380348)

29 May 2018

title

Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer. (English)

1 reference

29 May 2018

author name string

J Wang

1

1 reference

29 May 2018

P Song

2

1 reference

29 May 2018

S Schrieber

3

1 reference

29 May 2018

Q Liu

4

1 reference

29 May 2018

Q Xu

5

1 reference

29 May 2018

G Blumenthal

6

1 reference

29 May 2018

L Amiri Kordestani

7

1 reference

29 May 2018

P Cortazar

8

1 reference

29 May 2018

A Ibrahim

9

1 reference

29 May 2018

R Justice

10

1 reference

29 May 2018

Y Wang

11

1 reference

29 May 2018

S Tang

12

1 reference

29 May 2018

B Booth

13

1 reference

29 May 2018

N Mehrotra

14

1 reference

29 May 2018

A Rahman

15

1 reference

29 May 2018

language of work or name

English

0 references

publication date

31 January 2014

1 reference

29 May 2018

Clinical Pharmacology & Therapeutics

published in

1 reference

29 May 2018

volume

95

1 reference

29 May 2018

issue

5

1 reference

29 May 2018

page(s)

558-564

1 reference

29 May 2018

Trastuzumab emtansine for HER2-positive advanced breast cancer

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.24

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.24

Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.24

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.24

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.24

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.24

Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.24

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.24

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.24

Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.24

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.24

Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.24

Analysis of tumor burden versus progression-free survival for Phase II decision making.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.24

Performance status assessment in cancer patients. An inter-observer variability study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.24

Evidence for therapeutic drug monitoring of targeted anticancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.24

A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.24

Body surface area as a determinant of pharmacokinetics and drug dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.24

Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.24

Pharmacokinetic-Pharmacodynamic Relationships of Imatinib and Its Main Metabolite in Patients with Advanced Gastrointestinal Stromal Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.24

Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.24

Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.24

7 January 2021

A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.24

7 January 2021

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.24

7 January 2021

The Combination of Exposure-Response and Case-Control Analyses in Regulatory Decision Making

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.24

7 January 2021

Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.24

7 January 2021

The comparison of alternative smoothing methods for fitting non-linear exposure-response relationships with Cox models in a simulation study

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.24

7 January 2021

Identifiers

DOI

10.1038/CLPT.2014.24

1 reference

29 May 2018

1 reference

29 May 2018